Another Alzheimer's Drug Bites the Dust

08:57 EDT 12 Jul 2019 | Medscape

Amgen and Novartis will abandon work on umibecestat, an experimental BACE inhibitor for Alzheimer's disease, following evidence of worsening cognitive function in a clinical trial.
Medscape Medical News

Original Article: Another Alzheimer's Drug Bites the Dust


More From BioPortfolio on "Another Alzheimer's Drug Bites the Dust"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...